Skip to main content
. 2021 Nov 18;9(6):1579–1593. doi: 10.1016/j.gendis.2021.10.007

Table 3.

The most frequent genetic alterations of RIP kinases in human cancer.

RIP kinases Tumor types Number of cases Frequency of genetic alterations
Total Amplification Mutations
RIP1 Uterine Corpus Endometrial Carcinoma 529 6.99% 5.48% 1.51%
Ovarian Serous Cystadenocarcinoma 584 6.85% 5.99% 0.34%
Skin Cutaneous Melanoma 444 6.08% 2.93% 2.70%
Liver Hepatocellular Carcinoma 372 4.84% 3.76% 0.81%
RIP2 Breast Invasive Carcinoma 1084 9.04% 8.58% 0.28%
Uterine Carcinosarcoma 57 8.77% 8.77% 0%
Prostate Adenocarcinoma 494 7.89% 7.69% 0.20%
Liver Hepatocellular Carcinoma 372 7.53% 6.99% 0.27%
RIP3 Skin Cutaneous Melanoma 444 3.60% 0.23% 3.38%
Uterine Corpus Endometrial Carcinoma 529 3.59% 0.38% 3.21%
Bladder Urothelial Carcinoma 411 3.16% 0.73% 0.73%
Lung Adenocarcinoma 566 2.83% 1.77% 0.71%
RIP4 Skin Cutaneous Melanoma 444 5.86% 0.23% 5.41%
Stomach Adenocarcinoma 440 5.45% 0.23% 3.18%
Bladder Urothelial Carcinoma 411 4.62% 0.24% 3.89%
Uterine Corpus Endometrial Carcinoma 529 4.35% 0.76% 3.59%
RIP5 (Dusty Protein Kinase) Breast Invasive Carcinoma 1084 9.13% 8.49% 0.46%
Skin Cutaneous Melanoma 444 8.11% 3.15% 4.95%
Uterine Corpus Endometrial Carcinoma 529 7.56% 2.27% 5.29%
Liver Hepatocellular Carcinoma 372 6.72% 6.45% 0.27%
RIP5 (SgK288;ANKK1) Skin Cutaneous Melanoma 444 7.88% 0.23% 4.95%
Uterine Corpus Endometrial Carcinoma 529 6.05% 0% 5.48%
Uveal Melanoma 80 3.75% 0% 1.25%
Uterine Carcinosarcoma 57 3.51% 1.75% 0%
RIP6 (LRRK1) Sarcoma 255 10.20% 7.45% 2.35%
Uterine Corpus Endometrial Carcinoma 529 10.02% 0.76% 8.70%
Skin Cutaneous Melanoma 444 9.91% 1.13% 8.56%
Stomach Adenocarcinoma 440 9.09% 3.64% 5.23%
RIP7 (LRRK2) Uterine Corpus Endometrial Carcinoma 529 15.69% 0.76% 14.93%
Stomach Adenocarcinoma 440 14.55% 0.45% 13.86%
Lung Squamous Cell Carcinoma 487 13.96% 1.03% 12.73%
Skin Cutaneous Melanoma 444 13.29% 0.45% 12.61%